Regeneron and Sandoz have reached a settlement that resolves all patent litigation related to Sandoz’s biosimilar version of the eye disease drug Eylea. This agreement allows Sandoz to plan for the launch of its biosimilar by the end of 2026, marking a significant milestone in the competitive landscape of ophthalmic treatments.
The settlement comes at a time when the biosimilars market is rapidly evolving, driven by increasing demand for cost-effective alternatives to branded biologics. Eylea, a blockbuster drug for age-related macular degeneration and other retinal diseases, has generated substantial revenue for Regeneron, making its biosimilar an attractive target for Sandoz. The resolution of this litigation not only paves the way for Sandoz’s entry into the market but also signals a potential shift in pricing dynamics for Eylea, which could benefit healthcare systems and patients alike.
